Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new windowYouTube page opens in new window
[email protected]+61 3 9692 7222
PharmAust (PAA)
Cancer Therapeutics Research
PharmAust (PAA)
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT

Company Research

  • 2024
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Morgans – PharmAust Research Note

12/08/2024

Morgans – PharmAust Research Note

08/07/2024

Spark Plus – PharmAust Desk Note

16/01/2024

Morgans – PharmAust Business Summary Report

24/11/2022

Morgans Healthcare Research – PharmAust

24/11/2022

JP Equity Research Report

22/07/2022

JP Equity Partners – Broker Analyst Report – July 2020

News & Announcements 2020, Research Notes 2020By PharmAust30/06/2020

PAA Research Report – June 2020

Read more

PAA Research Report May 2020

Research Notes 2020By PharmAust28/05/2020

PAA Research Report – May 2020

Read more

PAA Research Report Sept

PAA_Research_Report_Sept.01

Drug Reformulation Play With Significant Potential

06/11/2018

Corporate Briefing Note

15/10/2017

Bioshares Report

22/09/2017

Argonaut Research Note

12/05/2017

Top 10 Spec Stocks 2017

20/03/2017

Argonaut Research Note

05/12/2016

Redchip

08/03/2016

Valuation of PharmAust Limited as at 31 August 2015

08/09/2015

RM Capital

11/11/2013
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER

PharmAust Follow

PharmAust is a clinical-stage biotech company focused on repurposing monepantel (MPL) for human neurodegenerative diseases ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
24 Jun

📸 Highlights from the MND Australia Global Day Event at Parliament House!

We teamed up with FightMND to raise awareness and fight for a future free of Motor Neurone Disease. 💙

#MNDAustralia #FightMND #MNDGlobalDay

Reply on Twitter 1805134834358210569 Retweet on Twitter 1805134834358210569 2 Like on Twitter 1805134834358210569 12 Twitter 1805134834358210569
Retweet on Twitter PharmAust Retweeted
stockheadau Stockhead @stockheadau ·
21 Jun

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
#ASX @PharmAust

Reply on Twitter 1803984607676654065 Retweet on Twitter 1803984607676654065 1 Like on Twitter 1803984607676654065 3 Twitter 1803984607676654065
pharmaust PharmAust @pharmaust ·
21 Jun

Exciting news for our investors! 🎉 Check out the details of our latest capital raise here: https://investorhub.pharmaust.com/investment-offer/32. Thank you for your continued support! 🌟 #PharmAust

Reply on Twitter 1804030728956711230 Retweet on Twitter 1804030728956711230 2 Like on Twitter 1804030728956711230 7 Twitter 1804030728956711230
Load More

Copyright © 2025 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top